Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Sep;81(1):75–79. doi: 10.1038/sj.bjc.6690653

Human germ cell tumours: expression of γ-glutamyl transpeptidase and sensitivity to cisplatin

M H Hanigan 1,2, H F Frierson Jr 3, V M Abeler 4, J Kaern 5, P T Taylor Jr 2
PMCID: PMC2374348  PMID: 10487615

Abstract

Previous studies have shown that the enzyme γ-glutamyl transpeptidase (GGT) is essential for the nephrotoxicity of cisplatin. This study was designed to determine whether GGT activity is necessary for the therapeutic effect of the drug. The relationship between GGT expression and clinical response to platinum-based chemotherapy was examined in 41 human germ cell tumours. Sections of formalin-fixed, paraffin-embedded tumours were immunohistochemically stained with an antibody directed against human GGT. There was no expression of GGT in any of the 17 seminomas or four dysgerminomas; whereas, 12/12 ovarian yolk sac tumours and 4/4 embryonal carcinomas of the testis were GGT-positive. In stage I tumours fewer tumour cells expressed GGT than in later stage tumours. In four germ cell tumours of mixed histology, the seminomatous and dysgerminoma areas were GGT-negative while the areas of the tumour with yolk sac or embryonal histology contained GGT-positive tumour cells. The patients with seminomas or dysgerminomas who were treated with cisplatin-based chemotherapy, all had a complete response despite the absence of GGT expression in these tumours. Fifteen of the 16 patients with yolk sac or embryonal carcinomas received cisplatin-based chemotherapy following surgery. Twelve had a complete response, while three failed to respond to platinum-based therapy. There was no correlation between the level of GGT-expression and response to therapy in this group. Three of the four patients with tumours of mixed histology were treated with cisplatin-based therapy, and had a complete response. Therefore, expression of GGT is not necessary for the therapeutic effect of cisplatin in germ cell tumours. The results from this study suggest that systemic inhibition of GGT would inhibit the nephrotoxic side-effect of cisplatin without interfering with its activity towards germ cell tumours. © 1999 Cancer Research Campaign

Keywords: glutathione, human tumours, platinum-based therapy, chemotherapy

Full Text

The Full Text of this article is available as a PDF (168.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bailey H. H., Gipp J. J., Mulcahy R. T. Increased expression of gamma-glutamyl transpeptidase in transfected tumor cells and its relationship to drug sensitivity. Cancer Lett. 1994 Dec 9;87(2):163–170. doi: 10.1016/0304-3835(94)90218-6. [DOI] [PubMed] [Google Scholar]
  2. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem. 1994 Jan 14;269(2):787–790. [PubMed] [Google Scholar]
  3. Einhorn L. H. Treatment of testicular cancer: a new and improved model. J Clin Oncol. 1990 Nov;8(11):1777–1781. doi: 10.1200/JCO.1990.8.11.1777. [DOI] [PubMed] [Google Scholar]
  4. Godwin A. K., Meister A., O'Dwyer P. J., Huang C. S., Hamilton T. C., Anderson M. E. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3070–3074. doi: 10.1073/pnas.89.7.3070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hanigan M. H. Expression of gamma-glutamyl transpeptidase provides tumor cells with a selective growth advantage at physiologic concentrations of cyst(e)ine. Carcinogenesis. 1995 Feb;16(2):181–185. doi: 10.1093/carcin/16.2.181. [DOI] [PubMed] [Google Scholar]
  6. Hanigan M. H., Frierson H. F., Jr, Brown J. E., Lovell M. A., Taylor P. T. Human ovarian tumors express gamma-glutamyl transpeptidase. Cancer Res. 1994 Jan 1;54(1):286–290. [PubMed] [Google Scholar]
  7. Hanigan M. H., Frierson H. F., Jr Immunohistochemical detection of gamma-glutamyl transpeptidase in normal human tissue. J Histochem Cytochem. 1996 Oct;44(10):1101–1108. doi: 10.1177/44.10.8813074. [DOI] [PubMed] [Google Scholar]
  8. Hanigan M. H., Frierson H. F., Jr, Taylor P. T., Jr Expression of gamma-glutamyl transpeptidase in stage III and IV ovarian surface epithelial carcinomas does not alter response to primary cisplatin-based chemotherapy. Am J Obstet Gynecol. 1998 Aug;179(2):363–367. doi: 10.1016/s0002-9378(98)70365-5. [DOI] [PubMed] [Google Scholar]
  9. Hanigan M. H., Gallagher B. C., Taylor P. T., Jr, Large M. K. Inhibition of gamma-glutamyl transpeptidase activity by acivicin in vivo protects the kidney from cisplatin-induced toxicity. Cancer Res. 1994 Nov 15;54(22):5925–5929. [PubMed] [Google Scholar]
  10. Hanigan M. H., Ricketts W. A. Extracellular glutathione is a source of cysteine for cells that express gamma-glutamyl transpeptidase. Biochemistry. 1993 Jun 22;32(24):6302–6306. doi: 10.1021/bi00075a026. [DOI] [PubMed] [Google Scholar]
  11. Hochwald S. N., Harrison L. E., Rose D. M., Anderson M., Burt M. E. gamma-Glutamyl transpeptidase mediation of tumor glutathione utilization in vivo. J Natl Cancer Inst. 1996 Feb 21;88(3-4):193–197. doi: 10.1093/jnci/88.3-4.193. [DOI] [PubMed] [Google Scholar]
  12. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  13. Segelov E., Campbell J., Ng M., Tattersall M., Rome R., Free K., Hacker N., Friedlander M. L. Cisplatin-based chemotherapy for ovarian germ cell malignancies: the Australian experience. J Clin Oncol. 1994 Feb;12(2):378–384. doi: 10.1200/JCO.1994.12.2.378. [DOI] [PubMed] [Google Scholar]
  14. Sepulveda A. R., Habib G. M., Damjanov A., Matacic S., Damjanov I., Lebovitz R. M., Lieberman M. W. Expression of gamma-glutamyl transpeptidase in midgestation mouse yolk sac and mouse visceral yolk sac carcinoma cells. Exp Cell Res. 1995 Aug;219(2):494–498. doi: 10.1006/excr.1995.1257. [DOI] [PubMed] [Google Scholar]
  15. van 't Sant P., Sleijfer D. T., Schraffordt Koops H., Suurmeijer A. J., Willemse P. H., De Bruijn H. W., Marrink J., Ockhuizen T. The pattern of gamma-glutamyl transpeptidase, alkaline phosphatase, serum glutamyl oxalate transaminase and serum glutamyl pyruvate transaminase in patients with disseminated non-seminomatous testicular tumors. Eur J Cancer Clin Oncol. 1984 Feb;20(2):209–215. doi: 10.1016/0277-5379(84)90186-x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES